Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_4
1
25%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

unknown1
Active, not recruiting1
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 22 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)

Trials by Status

unknown125%
active_not_recruiting125%
recruiting125%
not_yet_recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07601737
active_not_recruitingphase_2

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

NCT06771596
not_yet_recruitingphase_3

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

NCT06343116
unknownphase_4

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

NCT02293356

Clinical Trials (4)

Showing 4 of 4 trials
NCT07601737Phase 2

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
NCT06771596Phase 2

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Active Not Recruiting
NCT06343116Phase 3

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Not Yet Recruiting
NCT02293356Phase 4

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4